NeoGenomics (NEO)
(Delayed Data from NSDQ)
$16.28 USD
-0.20 (-1.21%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $16.30 +0.02 (0.12%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Cash flow Statements
Fiscal Year End for NeoGenomics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -87.97 | -144.25 | -8.35 | 4.17 | 8.01 |
Depreciation/Amortization & Depletion | 75.46 | 72.27 | 56.09 | 40.24 | 30.66 |
Net Change from Assets/Liabilities | -25.49 | -31.70 | -4.60 | -61.75 | -32.42 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 36.05 | 37.69 | -69.87 | 18.79 | 17.13 |
Net Cash From Operating Activities | -1.95 | -65.99 | -26.72 | 1.46 | 23.37 |
Property & Equipment | -28.75 | -18.79 | -64.14 | -29.10 | -20.03 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | -419.40 | -37.00 | 0.40 |
Investments | 105.46 | 19.31 | -133.82 | -93.35 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | -15.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 76.71 | 0.52 | -632.37 | -159.44 | -19.63 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 4.62 | 12.59 | 423.21 | 147.60 | 171.98 |
Issuance (Repayment) of Debt | -0.07 | -0.76 | 331.36 | 91.31 | -11.45 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -29.29 | -3.32 | -1.06 |
Net Cash from Financing Activities | 4.55 | 11.83 | 725.29 | 235.60 | 159.47 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 79.31 | -53.65 | 66.20 | 77.62 | 163.21 |
Cash at Beginning of Period | 263.18 | 316.83 | 250.63 | 173.02 | 9.81 |
Cash at End of Period | 342.49 | 263.18 | 316.83 | 250.63 | 173.02 |
Diluted Net EPS | -0.70 | -1.16 | -0.07 | 0.04 | 0.08 |
Fiscal Year End for NeoGenomics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -45.70 | -27.06 | -87.97 | -73.64 | -55.13 |
Depreciation/Amortization & Depletion | 37.83 | 18.99 | 75.46 | 56.38 | 37.52 |
Net Change from Assets/Liabilities | -26.05 | -9.56 | -25.49 | -29.13 | -13.41 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 21.90 | -8.29 | 36.05 | 26.66 | 16.78 |
Net Cash From Operating Activities | -12.02 | -25.92 | -1.95 | -19.74 | -14.24 |
Property & Equipment | -18.66 | -5.59 | -28.75 | -21.70 | -17.42 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 40.50 | 20.11 | 105.46 | 81.21 | 56.11 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 21.84 | 14.53 | 76.71 | 59.51 | 38.69 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.78 | 0.82 | 4.62 | 3.35 | 1.50 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | -0.07 | -0.07 | -0.06 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 2.78 | 0.82 | 4.55 | 3.28 | 1.44 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 12.60 | -10.57 | 79.31 | 43.06 | 25.89 |
Cash at Beginning of Period | 342.49 | 342.49 | 263.18 | 263.18 | 263.18 |
Cash at End of Period | 355.09 | 331.91 | 342.49 | 306.24 | 289.07 |
Diluted Net EPS | -0.15 | -0.21 | -0.11 | -0.15 | -0.19 |